Analyst Price Targets — LH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 11:40 am | David Westenberg | Piper Sandler | $300.00 | $285.30 | TheFly | Labcorp price target raised to $300 from $270 at Piper Sandler |
| February 18, 2026 12:48 pm | — | Robert W. Baird | $326.00 | $276.67 | TheFly | Labcorp price target raised to $326 from $313 at Baird |
| January 14, 2026 2:37 pm | — | Robert W. Baird | $313.00 | $259.18 | TheFly | Labcorp price target raised to $313 from $307 at Baird |
| October 29, 2025 12:55 pm | Kevin Caliendo | UBS | $320.00 | $253.74 | TheFly | Labcorp price target lowered to $320 from $325 at UBS |
| October 29, 2025 11:12 am | — | Robert W. Baird | $304.00 | $259.69 | TheFly | Labcorp price target lowered to $304 from $313 at Baird |
| October 28, 2025 5:09 pm | Michael Cherny | Leerink Partners | $342.00 | $261.63 | StreetInsider | Leerink on Laboratory Corporation of America (LH): 'Sell-off Unwarranted' |
| October 17, 2025 12:27 pm | — | UBS | $325.00 | $285.93 | TheFly | Labcorp price target raised to $325 from $305 at UBS |
| October 17, 2025 10:47 am | Ann Hynes | Mizuho Securities | $320.00 | $283.71 | TheFly | Labcorp price target raised to $320 from $285 at Mizuho |
| October 14, 2025 1:22 pm | — | Truist Financial | $320.00 | $278.42 | TheFly | Labcorp price target raised to $320 from $310 at Truist |
| October 3, 2025 12:25 pm | — | Evercore ISI | $305.00 | $279.44 | TheFly | Labcorp price target raised to $305 from $300 at Evercore ISI |
Latest News for LH
AISight® Dx will support fully digital workflows and AI-enabled insights across Labcorp's network of anatomic pathology labs and hospital collaborations to improve efficiency, collaboration and patient care BURLINGTON, N.C., Feb. 23, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight®…
Raiffeisen Bank International AG acquired a new position in Labcorp Holdings Inc. (NYSE: LH) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,068 shares of the medical research company's stock, valued at approximately $867,000. Other institutional investors
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Aberdeen Group plc reduced its stake in shares of Labcorp Holdings Inc. (NYSE: LH) by 8.1% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 68,544 shares of the medical research company's stock after selling 6,077 shares during the quarter. Aberdeen
Labcorp (NYSE: LH) executives said the company delivered what CEO Adam Schechter called a "very strong year" in 2025, citing more than 7% revenue growth, 13% adjusted EPS growth, and margin expansion of more than 50 basis points. On the company's fourth-quarter earnings call, management also introduced 2026 guidance that calls for continued growth and further
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.